Linaclotide in the management of gastrointestinal tract disorders

Drugs of Today

Volumn 48, Issue 3, 2012, Pages 197-206

  Lacy, Brian E ^a   Levenick, J M ^a   Crowell, M D ^b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Abdominal pain; Constipation; Guanylate cyclase; Irritable bowel syndrome; Linaclotide

Indexed keywords

CYCLIC GMP; GUANOSINE TRIPHOSPHATE; GUANYLIN; LINACLOTIDE; MD 1100; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; UROGUANYLIN;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; AREA UNDER THE CURVE; BINDING AFFINITY; BLEEDING; CHRONIC DISEASE; COMPETITIVE INHIBITION; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL TRANSIT; HEART ATRIUM FIBRILLATION; HUMAN; LYMPHOMA; MUCOSA; NONHUMAN; PATIENT SATISFACTION; POSTOPERATIVE PERIOD; QUALITY OF LIFE; REVIEW; STOMACH SECRETION; STROKE; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; BIOLOGICAL AVAILABILITY; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; CONSTIPATION; DRUG APPROVAL; DRUG INTERACTIONS; HUMANS; IRRITABLE BOWEL SYNDROME; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84859719909     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2012.48.3.1745228     Document Type: Review

References (42)

1. Higgins, P.D.R., Johanson, J.F. Epidemiology of chronic constipation in North America: A systematic review. Am J Gastroenterol 2004, 99(4): 750-9. (Pubitemid 38612817)
2. Irvine, E.J., Ferrazzi, S., Pare, P. et al. Health-related quality of life in functional GI disorders: Focus on constipation and resource utilization. Am J Gastroenterol 2002, 97(8): 1986-93.
3. Sonnenberg, A., Koch, T.R. Physician visits in the United States for constipation: 1958 to 1986. Dig Dis Sci 1989, 34(4): 606-11. (Pubitemid 19122000)
4. Cash, B.D., Lacy, B.E. Systematic review: FDA-approved prescription medications for adults with constipation. Gastroenterology & Hepatology 2006, 2(10): 736-49. (Pubitemid 44851258)
5. American College of Gastroenterology Task Force on Irritable Bowel Syndrome. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009, 104 (Suppl. 1): S1-S35.
6. Saito, Y.A., Locke, G.R., Talley, N.J. et al. A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome. Am J Gastroenterol 2000, 95(10): 2816-24.
7. Gralnek, I.M., Hays, R.D., Kilbourne, A. et al. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000, 119(3): 654-60.
8. Creed, F., Ratcliffe, J., Fernandez, L. et al. Health-related qualify of life and health care costs in severe, refractory irritable bowel syndrome. Ann Intern Med 2001, 134(9 Pt. 2): 860-8. (Pubitemid 32405694)
9. Frank, L., Kleinman, L., Rentz, A. et al. Health-related quality of life associated with irritable bowel syndrome: Comparison with other chronic diseases. Clin Ther 2002, 24(4): 675-89. (Pubitemid 34492889)
10. Eisen, G.M., Weinfurt, K.P., Hurley, J. et al. The economic burden of irritable bowel syndrome in a managed care organization. Am J Gastroenterol 2000, 95(9): 2628-9.
11. Longstreth, G.F., Wilson, A., Knight, K. et al. Irritable bowel syndrome, health care use, and costs: A U.S. managed care perspective. Am J Gastroenterol 2003, 98(3): 600-7. (Pubitemid 36348532)
12. Levy, R.L., Von Korff, M., Whitehead, W.E. et al. Costs of care for irritable bowel syndrome patients in a health maintenance organization. Am J Gastroenterol 2001, 96(11): 3122-9. (Pubitemid 33095351)
13. Lacy, B.E., Chey, W.D. Lubiprostone: Chronic constipation and irritable bowel syndrome with constipation. Expert Opin Pharmacother 2009, 10(1): 143-52.
14. Longstreth, G.F., Thompson, W.G., Chey, W.D. et al. Functional bowel disorders. Gastroenterology 2006, 130(5): 1480-91.
15. Wald, A., Scarpignato, C., Kamm, M.A. et al. The burden of constipation on quality of life: results of a multinational survey. Aliment Pharmacol Ther 2007, 26(2): 227-36. (Pubitemid 46985504)
16. Sun, S.X., DiBonaventura, M., Purayidathil, F.W. et al. Impact of chronic constipation on health-related quality of life, work productivity, and healthcare resource use: an analysis of the National Health and Wellness Survey. Dig Dis Sci 2011, 56(9): 2688-95.
17. Nyrop, K.A., Palsson, O.S., Levy, R.L. et al. Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain. Aliment Pharmacol Ther 2007, 26(2): 237-48. (Pubitemid 46985500)
18. Choung, R.S., Branda, M.E., Chitkara, D. et al. Longitudinal direct medical costs associated with constipation in women. Aliment Pharmacol Ther 2011, 33(2): 251-60.
19. Martin, B.C., Barghout, V., Cerulli, A. Direct medical costs of constipation in the United States. Manag Care Interface 2006, 19(12): 43-9. (Pubitemid 46146166)
20. Lacy, B.E., Weiser, K., De Lee, R. Tailored therapy for the treatment of irritable bowel syndrome. Therap Adv Gastroenterol 2009; 2(4): 221-38.
21. Busby, R.W., Bryant, A.P., Cordero, E.A. et al. The molecular target of MD-1100 is guanylate cyclase (GC-C), an apical receptor on intestinal epithelial cells. Gastroenterology [Dig Dis Week (May 14-19, Chicago) 2005] 2005, 128(4, Suppl. 2): A464.
22. Bryant, A.P., Busby, R., Cordero, E.A. et al. MD-1100, a therapeutic agent in development for the treatment of IBS-C, enhances intestinal secretion and transit, decreases visceral pain and is minimally absorbed in rats. Gastroenterology [Dig Dis Week (May 14-19, Chicago) 2005] 2005, 128(4, Suppl. 2): A464.
23. Currie, M.G., Fok, K.F., Kato, J. et al. Guanylin: an endogenous activator of intestinal guanylate cyclase. Proc Natl Acad Sci U S A 1992, 89(3): 947-51.
24. Hanra, F.K., Forte, L.R., Eber, S.L. et al. Uroguanylin: structure and activity of a second endogenous peptide that stimulates intestinal guanylate cyclase. Proc Natl Acad Sci U S A 1993, 90(22): 10464-8. (Pubitemid 23347062)
25. Vaandrager, A.B., Smolenski, A., Tilly, B.C. et al. Membrane targeting of cGMP-dependent protein kinase is required for cystic fibrosis transmembrane conductance regulator Cl-channel activation. Proc Natl Acad Sci U S A 1998, 95(4): 1466-71. (Pubitemid 28103415)
26. Bryant, A.P., Busby, R.W., Bartolini, W.P. et al. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci 2010, 86(19-20): 760-5.
27. Bueno, L., Beaufraud, C., Mahajan-Miklos, S. et al. Antinociceptive actions of MD-1100, a novel therapeutic agent for C-IBS, in animal models of visceral pain. Am J Gastroenterol [69th Annu Sci Meet Am Coll Gastroenterol (Oct 29-Nov 3, Orlando) 2004] 2004, 99(10, Suppl.): Abst 867.
28. Eutamene, H., Bradesi, S., Larauche, M.Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol Motil 2010, 22(3): 312-e84.
29. Bryant, A.P., Cordero, E.A., Tobin, J.V. et al. Linaclotide significantly improves post-operative ileus and opiate-induced constipation in rats. Am J Gastroenterol [71st Annu Sci Meet Am Coll Gastroenterol (Oct 20-25, Las Vegas) 2006] 2006, 101(Suppl. 2): Abst 1257.
30. Busby, R.W., Bryant, A.P., Bartolini, W.P. et al. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur J Pharmacol 2010, 649(1-3): 328-35.
31. Andresen, V., Camilleri, M., Busciglio, I.A. et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation- predominant irritable bowel syndrome. Gastroenterology 2007, 133(3): 761-8. (Pubitemid 47374145)
32. Johnston, J.M., Kurtz, C.B., Drossman, D.A. et al. Pilot study on the effect of linaclotide in patients with chronic constipation. Am J Gastroenterol 2009, 104(1): 125-32.
33. Currie, M.G., Kurtz, C., Mahajan-Miklos, et al. Effects of single dose administration of MD-1100 on safety, tolerability, exposure, and stool consistency in healthy subjects. Am J Gastroenterol [70th Annu Sci Meet Am Coll Gastroenterol (Oct 28-Nov 2, Honolulu) 2005] 2005, 100(9, Suppl.): Abst 894.
34. Johnston, J.M., Lavins, B.J., MacDougall, J.E. et al. Time to onset of linaclotide effect on the bowel habits in patients with chronic constipation: Results from a phase 2B study. Gastroenterology [Dig Dis Week (May 30-June 4, Chicago) 2009] 2009, 136(5, Suppl. 1): A537.
35. Lembo, A.J., Kurtz, C.B., MacDougall, J.E. et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology 2010, 138(3): 886-95.
36. Lavins, B.J., Johnston, J.M., MacDougall, J.E. et al. Effect of linaclotide on quality of life in adults with chronic constipation: Results from a phase 2B study. Gastroenterology [Dig Dis Week (May 30-June 4, Chicago) 2009] 2009, 136(5, Suppl. 1): A71.
37. Lembo, A.J., Schneier, H.A., Stevens, S.J. et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med 2011, 356(6): 527-36.
38. Johnston, J.M., Schneier, H., Lavins, B.J. Results from the randomized withdrawal period of a phase 3 clinical trial of linaclotide in chronic constipation. Gastroenterology [Dig Dis Week (May 1-6, New Orleans) 2010] 2010, 138(5, Suppl. 1): Abst T1817.
39. Carson, R.T., Tourkodimitris, S., MacDougall, J.E. et al. Effect of linaclotide on quality of life in adults with chronic constipation: Results from two randomized, double-blind, placebocontrolled phase 3 trials. Gastroenterology [Dig Dis Week (May 1-6, New Orleans) 2010] 2010, 139(1): E19.
40. Johnston, J.M., Kurtz, C.B., MacDougall, J.E. et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology 2010, 139(6): 1877-86.
41. Lembo, A.J., Johnston, J.M., Lavins, B.J. et al. Effect of linaclotide on IBS-C in the first week of treatment: Results from a phase 2B study. Gastroenterology [Dig Dis Week (May 30-June 4, Chicago) 2009] 2009, 136(5, Suppl. 1): Abst 157.
42. Carson, R., Williams, V., Nelsen, L. et al. Psychometric evaluation of patient-reported outcome measures for assessing IBS-C symptom severity and global change: Results from a phase 2b study of linaclotide. Am J Gastroenterol [74th Annu Sci Meet Am Coll Gastroenterol (Oct 23-28, San Diego) 2009], 2009, 104(Suppl. 3): Abst 1113.